Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
about
Copine-III interacts with ErbB2 and promotes tumor cell migrationThe atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cellsDistinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcomeOncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptorEngulfment protein GULP is regulator of transforming growth factor-β response in ovarian cells.Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapyLysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.Transcriptional program induced by Wnt protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments.DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage.VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.Fgf9 from dermal γδ T cells induces hair follicle neogenesis after woundingAberrant expression of a beta-catenin gain-of-function mutant induces hyperplastic transformation in the mouse cornea.Estimating developmental states of tumors and normal tissues using a linear time-ordered model.Differential expression of CHL1 gene during development of major human cancers.Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.Robust multi-tissue gene panel for cancer detectionIn Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer.Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.Role of Pirh2 in mediating the regulation of p53 and c-Myc.Gene expression profiling of embryonic human neural stem cells and dopaminergic neurons from adult human substantia nigraMesothelial- and epithelial-derived FGF9 have distinct functions in the regulation of lung development.Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas.A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study.Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability.AUF1 p42 isoform selectively controls both steady-state and PGE2-induced FGF9 mRNA decay.Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer markerFUBP3 interacts with FGF9 3' microsatellite and positively regulates FGF9 translationA method for visualization of "omic" datasets for sphingolipid metabolism to predict potentially interesting differences.miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer.Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis.Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.Identification of a novel inhibitor of the canonical Wnt pathway.Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling.
P2860
Q22001536-3F15136F-08C0-4C05-A6D4-12895F9C21D6Q24322930-25C4FBB0-6E1A-4FED-8819-24E9071FAADDQ28273187-1EAC1DB5-BC82-4F7B-83EE-C9DEEEBA4ABDQ28304891-FE91343A-A351-4ED1-8088-E5663D87B84EQ30418853-5D92C87D-B6AA-4535-BB52-04AB55B2CD54Q30434260-06A2D7E2-CF6D-4E71-A3F9-0DC72D4BC02FQ30489645-E5C13012-41EB-4429-8D2F-DE375187B12AQ33300355-C9A60239-662E-44A2-BF75-DA981AA0E468Q33372943-B024BABD-2F5A-4F50-BF5E-028F62E35D93Q33425221-5C284152-9C11-456F-9735-A68930139551Q33631866-50E5731E-F5EE-489B-B437-568851B953F4Q33688934-6D6DD8B5-A88E-46D4-B714-DB43940A8413Q33694015-070FDEAD-DF9B-412E-B02A-B14A3C2484ADQ33709977-2950D73D-B44D-4C13-9292-C123F54C4769Q33745623-EF6C9C3B-2545-4700-A7A4-6765F8ECC892Q33763816-B858858C-132F-43CB-A9DB-E2AC8C120199Q33817598-2C93EE2A-5EA3-42E3-99D3-E5569477E90FQ33847826-043FFB74-F9E7-4F4A-9A7E-938CE0F69875Q33986224-0E53A7F8-3639-42A9-AB86-5C22099749FAQ34004624-CEA04BEB-DD77-4466-8BD6-A05E552A77AFQ34021008-E7BCF699-FF2A-4915-8FE6-EFF65D67CDB8Q34069663-6CDFDFE8-1ED3-4A86-9BF4-E2C61FE80B3FQ34085616-ED6E5B80-3D84-4E6F-9D22-9820F0505E36Q34098187-725F73CF-CB16-4629-AB75-75B20B7F4E56Q34199875-E8BC4355-39DA-4809-A7CE-0C14CC40D7D8Q34337631-991A0309-E97A-4B49-A1AD-57E06510D7A6Q34348077-7E264F42-095C-4B6C-A1CB-E3268F38F8BEQ34352173-B4E3ECDF-DC64-4A37-9D4A-328DE0EAAB6EQ34401473-6EB5F67D-207A-486A-BBC2-9E0EC6AA3FCFQ34630557-0116B010-27AE-4792-BE8E-FFFC6BB330DEQ34639059-EA97A904-DF61-4033-9BCB-37800688C784Q34946895-8F8EA2BF-E117-4150-86DA-463989CA18EFQ34955765-35AE4625-6310-4A2A-8A29-3AC8BC04BB19Q34981594-BB118CAF-106F-4464-A4B5-1FF511F46F07Q34990141-77D84069-1A94-4764-8166-B0B085A919A3Q35020913-9DEA662C-F36B-4FBC-B937-0E6ECBDDA4ADQ35096644-C4BAFDE6-5B25-4421-BEC1-8EE50A08C31DQ35098085-5F7B6A57-CE8E-4034-A2EC-5E7027AB77C6Q35118920-0A2B5D3D-9498-4C67-B884-814054D6562AQ35131505-E31E4963-4328-4BAD-94F3-E31C7CD6B84C
P2860
Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Fibroblast growth factor 9 has ...... endometrioid adenocarcinomas.
@en
type
label
Fibroblast growth factor 9 has ...... endometrioid adenocarcinomas.
@en
prefLabel
Fibroblast growth factor 9 has ...... endometrioid adenocarcinomas.
@en
P2093
P1433
P1476
Fibroblast growth factor 9 has ...... endometrioid adenocarcinomas.
@en
P2093
Donald R Schwartz
Eric R Fearon
Kathleen R Cho
Neali D Hendrix
Rork Kuick
P304
P356
10.1158/0008-5472.CAN-05-3694
P407
P577
2006-02-01T00:00:00Z